Penetration of HIV‐1 protease inhibitors into CSF and semen
Open Access
- 1 July 2000
- journal article
- review article
- Published by Wiley in HIV Medicine
- Vol. 1 (s2) , 18-22
- https://doi.org/10.1046/j.1468-1293.2000.00002.x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Antiretroviral-Drug Concentrations in SemenAntimicrobial Agents and Chemotherapy, 2000
- News from the 7th Conference on Retroviruses and Opportunistic InfectionsInpharma Weekly, 2000
- Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitorsAIDS, 2000
- The Effect of Increasing α1‐Acid Glycoprotein Concentration on the Antiviral Efficacy of Human Immunodeficiency Virus Protease InhibitorsThe Journal of Infectious Diseases, 1999
- Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasmaSexually Transmitted Infections, 1999
- Plasma and Cerebrospinal Fluid Saquinavir Concentrations in Patients Receiving Combination Antiretroviral TherapyClinical Infectious Diseases, 1999
- Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency VirusVirology, 1998
- In Vitro Blood–Brain Barrier Permeability of Nevirapine Compared to Other HIV Antiretroviral AgentsJournal of Pharmaceutical Sciences, 1998
- HIV-1 Protease Inhibitors Are Substrates for theMDR1 Multidrug TransporterBiochemistry, 1998
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998